Prof Chan Cheah: BTKi combination shows ‘encouraging clinical activity’ in B-cell malignancies

Covering new research into the BTK inhibitor TG-1701 in CLL, Professor Chan Cheah haematologist and lymphoma lead at Sir Charles Gairdner Hospital  in WA presented updated results at ASCO 2021 of the agent as monotherapy and in combination with ublituximab and umbralisib (U2) in patients with B-cell malignancies. Addressing delegates in the virtual session, Professor ...

Already a member?

Login to keep reading.

© 2022 the limbic